Dabur Pharma

Fresenius Kabi Oncology, formerly known as Dabur Pharma, is a prominent pharmaceutical company specializing in the development and manufacture of generic anti-cancer drugs. Originally established as the oncology division of Dabur India, it was spun off as an independent entity in 2003 before being acquired by the German healthcare giant Fresenius Kabi in 2008. The company is a global leader in the production of cytotoxic agents, offering a comprehensive portfolio of chemotherapy products including paclitaxel, docetaxel, and oxaliplatin. With state-of-the-art manufacturing facilities in India that are approved by major regulatory bodies like the US FDA and UK MHRA, it supplies oncology medicines to over 40 countries. The company's integration into Fresenius Kabi has expanded its reach, making it a critical component of the parent organization's global oncology platform.